• Margin expansion drivers: Revenue grew 21% year-on-year compared to a 4% headcount increase, driven by AI and robotic process automation. Excluding a ₹20 crore one-time TrueBridge acquisition expense, EBITDA stood at ₹314 crore with margins surpassing 35%.
• Long-term EBITDA guidance: Pro-forma blended margins will temporarily drop to 26–27% following the TrueBridge acquisition before returning to the 33–35% range within 1–2 years. Management targets growing trailing 12-month EBITDA from ₹1,148 crore to ₹3,000 crore by FY30.
• Cross-selling traction: Cross-sell momentum is led by AI-enabled revenue cycle management, proprietary AI medical coding, and clinical data extraction for electronic health records. Existing wallet share penetration across more than 600 large clients remains under 20%.
• Deal pipeline growth: The standalone deal pipeline is at an all-time high, highlighted by recent expansions with major industry leaders, including Advocate Health with over $30 billion in annual revenue.